Carregant...
A PET study in healthy subjects of brain exposure of (11)C-labelled osimertinib – A drug intended for treatment of brain metastases in non-small cell lung cancer
Osimertinib is a tyrosine kinase inhibitor (TKI) of the mutated epidermal growth factor receptor (EGFRm) with observed efficacy in patients with brain metastases. Brain exposure and drug distribution in tumor regions are important criteria for evaluation and confirmation of CNS efficacy. The aim of...
Guardat en:
| Publicat a: | J Cereb Blood Flow Metab |
|---|---|
| Autors principals: | , , , , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
SAGE Publications
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7168784/ https://ncbi.nlm.nih.gov/pubmed/31006308 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/0271678X19843776 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|